Novartis10h
Zaposlitev v Novartisu v Sloveniji
V Novartisu spodbujamo inovativnost in razvoj ter delujemo na številnih področjih. Tudi vi lahko postanete del tega, del naše zgodbe. Pridružite se naši ustvarjalni skupnosti strokovnjakov in našli ...
Novartis12h
Postes vacants / Novartis France
Leader mondial dans le domaine de la santé, Novartis propose actuellement l’un des portefeuilles les plus complets du marché. Un portefeuille de médicaments innovants, développés par des personnes ...
Novartis1d
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...
Novartis1d
Career search
Job Title Sort ascending Business Location Site Date Posted Therapeutic Area Partner Regular (Sales), Full time Innovative Medicines Utd.Arab Emir. Dubai Feb 03, 2025 Senior Specialist, IT Information ...
Novartis2d
Career Search
Job Title Sort ascending Business Location Site Date Posted Consultor Técnico Especialidades Sênior Regular (Vendas), Full time Innovative Medicines Brazil Santo Amaro Feb 05, 2025 MSL, Temporary ...
Novartis5d
县域主任/县域主管
诺华 承 诺 与残障人士共事并 为 他 们 提供合理的便利 设 施。如果您由于健康状况或残障 在招聘 过 程的任何 环 节 需要合理便利 设 施 或者 为 了履行 职 位的基本 职 能 请发 送 电 子 邮 件 ...
Novartis8d
Višji poslovni partner za pridobivanje talentov in zaposlovanje (m/ž/d) / Senior TAS Business Partner (m/f/d)
Why Novartis: Helping people with disease and their families takes more than innovative science. It takes a community of smart, passionate people like you. Collaborating, supporting and inspiring each ...
Novartis9d
Field Medical Lead (Renal)
Why Novartis: Helping people with disease and their families takes more than innovative science. It takes a community of smart, passionate people like you. Collaborating, supporting and inspiring each ...
Novartis12d
Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024
Net sales grew +12% (cc 1, +11% USD) with core operating income 1 up +22% (cc, +19% USD) Sales growth driven by continued st ...
Novartis12d
Novartis setzt die starke Umsatzdynamik mit Margenerhöhungen fort und erreicht 2024 wichtige Meilensteine bei Innovationen
1. Die Angaben in konstanten Wechselkursen (kWk), die Kernergebnisse und der Free Cashflow sind Nicht-IFRS-Kennzahlen. Erläuterungen der Nicht-IFRS-Kennzahlen finden sich auf Seite 47 der in ...
Novartis14d
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...